Dauntless 1


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Dauntless 1 is developing a therapeutic agent, DP1038, for the treatment of endocrine cancers in Dauntless 1. DP1038 will follow a 505(b)(2) pathway to speed development and reduce costs. DP1038 completed nonclinical toxicology studies in 2016 and will be evaluated in a Phase 1 first-in-human clinical trial in early 2017.

Dauntless 1 is developing a therapeutic agent, DP1038, for the treatment of endocrine cancers in Dauntless 1. DP1038 will follow a 505(b)(2) pathway to speed development and reduce costs. DP1038 completed nonclinical toxicology studies in 2016 and wi...Show all

Company (Alive / Active)

Phone: 858-922-8919

Fax:

12520 High Bluff Drive
Suite 380
San Diego, 92130
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Dauntless 1 $20M Jan 7, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Dauntless 1 Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Canaan PartnersVenture CapitalMenlo Park, California, United StatesSeries A
Undisclosed InvestorsOther
Sofinnova VenturesVenture CapitalMenlo Park, California, United StatesSeries B, Series A
See all 3 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)